Back to Careers

CEO. Dr. Hanadie Yousef participates in AFAR’s webinar on AI + Longevity Drug Discovery

Back to Careers

CEO Dr. Hanadie Yousef gives a talk on Juvena’s AI-enabled protein drug discovery and development platform and lead therapeutic candidates for muscle regeneration and enhancing fat metabolism at the Longevity Summit Dublin

Back to Careers

Dr. Jeremy O’Connell, Director of translation Dr. Priya Handa, and Scientist Dr. Ritwik Datta attend and present our latest results at ENDO 2024, highlighting how  JUV-112 Offers a Distinctive Approach to Weight Loss and Metabolic Health

Back to Careers

Dr. Jeremy O’Connell, Director of translation Dr. Priya Handa, and Scientist Dr. Ritwik Datta attend and present our latest results at ENDO 2024, highlighting how  JUV-112 Offers a Distinctive Approach to Weight Loss and Metabolic Health

Back to Careers

Juvena’s Director of Discovery & Platform, Dr. Thach Mai presents “Mapping the therapeutic potential of secreted proteins through integrating AI and quantitative multi-omics technology” at the Element Biosciences Roadshow

Back to Careers

CEO and co-Founder Dr. Hanadie Yousef recognized as In Vivo’s 2024 Rising Leaders, which includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.

Back to Careers

One of In Vivo’s 2024 Rising Leaders, Dr. Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company’s lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.

Back to Careers

Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.

Back to Careers

CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit 

Back to Careers

Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.